几种规模化种植重楼属植物化学物质基础研究

我国是重楼属（Paris）植物遗传资源最丰富和利用最广泛的国家，但重楼属绝大多数物种处于濒危状态。最近10年，重楼的人工种植发展迅速，但种源多为就地取材，一方面造成重楼属野生资源的巨大破坏；另一方面造成非《中华人民共和国药典》收录物种出现规模化种植的局面，给中药质量管理带来挑战，给种植户带来风险。是直接抛弃这些非《药典》物种，还是开发利用它们？并没有现成的答案。本项目在前期研究积累基础上，采用民族植物学、植物化学、药理学等方法和手段，对重楼属植物野外资源状况以及人工种植和民间利用情况进行调查，选择5种非《药典》收载的地方优势种开展化学物质基础及药理活性的研究，并跟《药典》收载物种滇重楼P. polyphylla var. yunnanensis进行对比，为重楼属植物的生物多样性保护和资源的可持续利用奠定理论基础。

China is the country with the most abundant genetic resources, and with the most extensive utilization of the genus of Paris. Most of Paris plants are endangered. Recently 10 years, cultivation of Paris plants has sprung up with Paris provenances collected mainly from local aeras. On the one hand, wild Paris resources are being destroyed enormously. On the other hand, those Paris plants which were not included in Pharmacopoeia of the People's Republic of China were cultivated at a large scale, to challenge the quality management of traditional Chinese medicines and to bring risks to local farmers. Up to now, there is no answer on whether these non-included Paris species in Pharmacopoeia should be discarded or should be developed and utilized. Based on our previous studies, through the approaches of ethnobotany, phytochemistry, and pharmacology and other methods, the status of the wild Paris resources, as well as the traditional knowledge of managing and using Paris resources will be systematically investigated and documented in the proposed project, and five endemic or dominant Paris species which were not included in Pharmacopoeia will be selected for phytochemical and pharmacological studies, which will be compared with P. polyphylla var. yunnanensis, a species in Pharmacopoeia. The research results will provide a scientific basis and theoretical foundation for the conservation of biodiversity and the sustainable use of resources of Paris.